Io­n­is, Cy­cle­ri­on tout pos­i­tive da­ta read­outs; MA­IA prices first biotech IPO in over two months

Io­n­is put out pos­i­tive topline re­sults from a Phase IIb tri­al on end-stage re­nal dis­ease, in­ves­ti­gat­ing pa­tients on dial­y­sis.

The drug can­di­date, fe­s­om­ersen, achieved its pri­ma­ry goal of “no in­crease in in­ci­dence of ma­jor bleed­ing and clin­i­cal­ly rel­e­vant non-ma­jor bleed­ing,” com­pared to place­bo. The study, named RE-THINC ES­RD, was con­duct­ed by Bay­er, which li­censed the drug from Io­n­is.

Spe­cif­ic da­ta will be pre­sent­ed at a lat­er date at an undis­closed, up­com­ing med­ical meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER